The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Drug combination therapy increases successful drug repositioning
Open accessAbstract
Repositioning of approved drugs has recently gained new momentum for rapid identification and development of new therapeutics for diseases that lack effective drug treatment. Reported repurposing screens have increased dramatically in number in the past five years. However, many newly identified compounds have low potency; this limits their immediate clinical applications because the known, tolerated plasma drug concentrations are lower than the required therapeutic drug concentrations. Drug combinations of two or more compounds with different mechanisms of action are an alternative approach to increase the success rate of drug repositioning.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
Network medicine: a network-based approach to human disease
Barabási, A.-L., Gulbahce, N., & Loscalzo, J. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2918 · Cited by 5,034
Spread of Artemisinin Resistance in Plasmodium falciparum Malaria
Ashley, E. A., Dhorda, M., Fairhurst, R. M., Amaratunga, C., Lim, P., Suon, S., Sreng, S., Anderson, J. M., Mao, S., Sam, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314981 · Cited by 2,205
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Boolell, M., Mj, A., Sa, B., Gepi-Attee, S., Muirhead, G. J., Naylor, A. M., Ih, O., & Gingell, C. (1996) · PubMed · Cited by 1,067
Mechanisms of drug combinations: interaction and network perspectives
Jia, J., Zhu, F., Ma, X., Cao, Z. W., Li, Y. X., & Chen, Y. Z. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2683 · Cited by 969
Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951
Large-scale prediction and testing of drug activity on side-effect targets
Lounkine, E., Keiser, M. J., Whitebread, S., Mikhailov, D., Hamon, J., Jenkins, J. L., Lavan, P., Weber, E., Doak, A. K., Côté, S., et al. (2012) · Nature · doi:10.1038/nature11159 · Cited by 881
The efficiency of multi-target drugs: the network approach might help drug design
CSERMELY, P., AGOSTON, V, & PONGOR, S. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.02.007 · Cited by 803
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
Crystal, A. S., Shaw, A. T., Sequist, L. V., Friboulet, L., Niederst, M. J., Lockerman, E. L., Frias, R. L., Gainor, J. F., Amzallag, A., Greninger, P., et al. (2014) · Science · doi:10.1126/science.1254721 · Cited by 708
A network dysfunction perspective on neurodegenerative diseases
Palop, J. J., Chin, J., & Mucke, L. (2006) · Nature · doi:10.1038/nature05289 · Cited by 692
Targeting the cancer kinome through polypharmacology
Knight, Z. A., Lin, H., & Shokat, K. M. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2787 · Cited by 674
Intrinsic Membrane Hyperexcitability of Amyotrophic Lateral Sclerosis Patient-Derived Motor Neurons
Wainger, B. J., Kiskinis, E., Mellin, C., Wiskow, O., Han, S. S. W., Sandoe, J., Perez, N. P., Williams, L. A., Lee, S., Boulting, G., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.019 · Cited by 662
The RCSB Protein Data Bank: views of structural biology for basic and applied research and education
Rose, P. W., Prlić, A., Bi, C., Bluhm, W. F., Christie, C. H., Dutta, S., Green, R. K., Goodsell, D. S., Westbrook, J. D., Woo, J., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1214 · Cited by 515
Kelly, C. M., Juurlink, D. N., Gomes, T., Duong-Hua, M., Pritchard, K. I., Austin, P. C., & Paszat, L. F. (2010) · BMJ · doi:10.1136/bmj.c693 · Cited by 466
Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination
Zhanel, G. G., Lawson, C. D., Adam, H., Schweizer, F., Zelenitsky, S., Lagacé-Wiens, P. R. S., Denisuik, A., Rubinstein, E., Gin, A. S., Hoban, D. J., et al. (2013) · Drugs · doi:10.1007/s40265-013-0013-7 · Cited by 433
Time to Hit HIV, Early and Hard
Ho, D. D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508173330710 · Cited by 431
Phenotypic screens as a renewed approach for drug discovery
Zheng, W., Thorne, N., & McKew, J. C. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.001 · Cited by 423
Self-citationJin, G., & Wong, S. T. C. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.005 · Cited by 416
Huang, R., Southall, N., Wang, Y., Yasgar, A., Shinn, P., Jadhav, A., Nguyen, D.-T., & Austin, C. P. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001862 · Cited by 401
Zilberberg, M. D., Shorr, A. F., Micek, S. T., Vazquez-Guillamet, C., & Kollef, M. H. (2014) · Critical Care · doi:10.1186/preaccept-6556009101270526 · Cited by 340
Fyn inhibition rescues established memory and synapse loss in Alzheimer mice
Kaufman, A. C., Salazar, S. V., Haas, L. T., Yang, J., Kostylev, M. A., Jeng, A. T., Robinson, S. A., Gunther, E. C., van Dyck, C. H., Nygaard, H. B., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24394 · Cited by 314
A clinical drug library screen identifies astemizole as an antimalarial agent
Chong, C. R., Chen, X., Shi, L., Liu, J. O., & Sullivan, D. J. (2006) · Nature Chemical Biology · doi:10.1038/nchembio806 · Cited by 289
Similarity-based modeling in large-scale prediction of drug-drug interactions
Vilar, S., Uriarte, E., Santana, L., Lorberbaum, T., Hripcsak, G., Friedman, C., & Tatonetti, N. P. (2014) · Nature Protocols · doi:10.1038/nprot.2014.151 · Cited by 280
Polypharmacology in a Single Drug: Multitarget Drugs
L. Bolognesi, M. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320130004 · Cited by 230
Kouznetsova, J., Sun, W., Martínez-Romero, C., Tawa, G., Shinn, P., Chen, C. Z., Schimmer, A., Sanderson, P., McKew, J. C., Zheng, W., et al. (2014) · Emerging Microbes & Infections · doi:10.1038/emi.2014.88 · Cited by 227
Self-citationInhibition of Angiogenesis by the Antifungal Drug Itraconazole
Chong, C. R., Xu, J., Lu, J., Bhat, S., Sullivan, D. J., & Liu, J. O. (2007) · ACS Chemical Biology · doi:10.1021/cb600362d · Cited by 210
Mu, J., Myers, R. A., Jiang, H., Liu, S., Ricklefs, S., Waisberg, M., Chotivanich, K., Wilairatana, P., Krudsood, S., White, N. J., et al. (2010) · Nature Genetics · doi:10.1038/ng.528 · Cited by 195
Wang, J., Gines, S., MacDonald, M. E., & Gusella, J. F. (2005) · BMC Neuroscience · doi:10.1186/1471-2202-6-1 · Cited by 179
Human stem cells and drug screening: opportunities and challenges
Ebert, A. D., & Svendsen, C. N. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3000 · Cited by 172
Nygaard, H. B., Wagner, A. F., Bowen, G. S., Good, S. P., MacAvoy, M. G., Strittmatter, K. A., Kaufman, A. C., Rosenberg, B. J., Sekine-Konno, T., Varma, P., et al. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0119-0 · Cited by 165
Rudin, C. M., Brahmer, J. R., Juergens, R. A., Hann, C. L., Ettinger, D. S., Sebree, R., Smith, R. D., Aftab, B. T., Huang, P., & Liu, J. O. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31828c3950 · Cited by 157
Chemical Genomic Profiling for Antimalarial Therapies, Response Signatures, and Molecular Targets
Yuan, J., Cheng, K. C.-C., Johnson, R. L., Huang, R., Pattaradilokrat, S., Liu, A., Guha, R., Fidock, D. A., Inglese, J., Wellems, T. E., et al. (2011) · Science · doi:10.1126/science.1205216 · Cited by 142
Drug–drug interactions during antiviral therapy for chronic hepatitis C
Kiser, J. J., Burton, J. R., & Everson, G. T. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.106 · Cited by 134
Duke, J. D., Han, X., Wang, Z. P., Subhadarshini, A., Karnik, S., Li, X., Hall, S. D., Jin, Y., Callaghan, J. T., Overhage, J. M., et al. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002614 · Cited by 132
Attarian, S., Vallat, J., Magy, L., Funalot, B., Gonnaud, P., Lacour, A., Péréon, Y., Dubourg, O., Pouget, J., Micallef, J., et al. (2014) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-014-0199-0 · Cited by 130
Xu, M., Liu, K., Swaroop, M., Porter, F. D., Sidhu, R., Finkes, S., Ory, D. S., Marugán, J., Xiao, J., Southall, N. T., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.357707 · Cited by 125
Self-citationMullard, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4545 · Cited by 119
Lead-like, drug-like or “Pub-like”: how different are they?
Oprea, T. I., Allu, T. K., Fara, D. C., Curpan, R. F., Ostopovici, L., & Bologa, C. (2007) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-007-9105-3 · Cited by 114
Mott, B. T., Eastman, R. T., Guha, R., Sherlach, K. S., Siriwardana, A., Shinn, P., McKnight, C. G., Michael, S., Lacerda‐Queiroz, N., Patel, P., et al. (2015) · Scientific Reports · doi:10.1038/srep13891 · Cited by 112
Yu, Z., Zhao, G., Xie, G., Zhao, L., Chen, Y., Yu, H., Zhang, Z., Li, C., & Li, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.5405 · Cited by 106
Combination therapies in oncology
Webster, R. M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.3 · Cited by 106
Exploiting polypharmacology for drug target deconvolution
Gujral, T. S., Peshkin, L., & Kirschner, M. W. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1403080111 · Cited by 102
Carlson, C. B., Koonce, C. H., Aoyama, N., Einhorn, S., Fiene, S., Thompson, A., Swanson, B., Anson, B. D., & Kattman, S. J. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113500812 · Cited by 100
Optimization of drug combinations using Feedback System Control
Nowak-Sliwinska, P. M., Weiss, A., Ding, X., Dyson, P. J., van den Bergh, H., Griffioen, A. W., & Ho, C. (2016) · Nature Protocols · doi:10.1038/nprot.2016.017 · Cited by 100
Synergy Testing of FDA-Approved Drugs Identifies Potent Drug Combinations against Trypanosoma cruzi
Planer, J. D., Hulverson, M. A., Arif, J. A., Ranade, R. M., Don, R., & C, F. S. B. A. (2014) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0002977 · Cited by 94
DAUD, A. I., Krishnamurthi, S., Saleh, M. N., Gitlitz, B. J., Borad, M. J., Gold, P. J., Chiorean, E. G., Springett, G. M., Abbas, R., Agarwal, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2378 · Cited by 92
Multi‐Objective Molecular De Novo Design by Adaptive Fragment Prioritization
Reutlinger, M., Rodrigues, T., Schneider, P., & Schneider, G. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201310864 · Cited by 89
Markowitz, M. H., Evering, T. H., Garmon, D., Caskey, M. F., Mar, M. L., Rodriguez, K., Sahi, V., Palmer, S., Prada, N., & Mohri, H. (2014) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000111 · Cited by 78
Computational polypharmacology comes of age
Rastelli, G., & Pinzi, L. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00157 · Cited by 69
Sandercock, A. M., Rust, S. J., Guillard, S., Sachsenmeier, K. F., Holoweckyj, N., Hay, C. M., Flynn, M., Huang, Q., Yan, K., Herpers, B., et al. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0415-0 · Cited by 56
Chen, B. D., Greenside, P., Paik, H., Sirota, M., Hadley, D., & Butte, A. J. (2015) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12009 · Cited by 51
Barneh, F., Jafari, M., & Mirzaie, M. (2015) · Briefings in Bioinformatics · doi:10.1093/bib/bbv094 · Cited by 50
Multidimensional De Novo Design Reveals 5‐HT2B Receptor‐Selective Ligands
Rodrigues, T., Hauser, N., Reker, D., Reutlinger, M., Wunderlin, T., Hamon, J., Koch, G., & Schneider, G. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201410201 · Cited by 41
Essential medicines are still essential
Gray, A., Wirtz, V. J., Hoen, E. ‘., Reich, M. R., & Hogerzeil, H. V. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00514-0 · Cited by 35
Titus, S. A., Southall, N. T., Marugán, J., Austin, C. P., & Zheng, W. (2012) · Current Chemical Genomics · doi:10.2174/1875397301206010079 · Cited by 29
Self-citationde Bie, S., Coloma, P. M., Ferrajolo, C., Verhamme, K. M. C., Trifirò, G., Schuemie, M. J., Straus, S. M. J. M., Gini, R., Herings, R. M. C., Mazzaglia, G., et al. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12610 · Cited by 27
A novel algorithm for analyzing drug-drug interactions from MEDLINE literature
Lu, Y., Shen, D., Pietsch, M., Nagar, C., Fadli, Z., Huang, H., Tu, Y.-C., & Cheng, F. (2015) · Scientific Reports · doi:10.1038/srep17357 · Cited by 27
Cited by
Xu, M., Lee, E. M., Wen, Z., Cheng, Y., Huang, W.-K., Qian, X., TCW, J., Kouznetsova, J., Ogden, S. C., Hammack, C., et al. (2016) · Nature Medicine · doi:10.1038/nm.4184 · Cited by 641
Self-citationOvercoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 516
Machine learning approaches to drug response prediction: challenges and recent progress
Adam, G., Rampášek, L., Safikhani, Z., Smirnov, P., Haibe-Kains, B., & Goldenberg, A. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-0122-1 · Cited by 425
Drug repurposing for antimicrobial discovery
Farha, M. A., & Brown, E. D. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0357-1 · Cited by 360
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells
Garg, P., Malhotra, J., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. (2024) · Cancers · doi:10.3390/cancers16132478 · Cited by 339
Metadata
- Authors
- Sun, W., Sanderson, P. E., & Zheng, W.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2016-07
- Volume
- 21
- Issue
- 7
- Pages
- 1189-1195
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2399140686
- Cited by
- 436
- References
- 58
- FWCI
- 19.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.